Host: Università degli Studi di Ferrara
Contact: firstname.lastname@example.org | email@example.com | firstname.lastname@example.org
There are treatments, such as in the case of coagulation diseases such as haemophilia, which require protein-based drugs with the aim of “correcting” the defect (e.g. bleeding) by restoring normal biological function (e.g. blood clotting ). Like all drugs, these proteins also have a limited duration (half-life). Biotechnologies can therefore provide excellent tools (protein engineering) to specifically modify these therapeutic proteins in order to make them more effective. Speaker: Alessio Branchini.